NOVARTIS N news, videos and press releases - Page 2
For more news please use our advanced search feature.
NOVARTIS N - More news...
NOVARTIS N - More news...
- Shareholder Alert: Ademi LLP investigates whether Chinook Therapeutics, Inc. has obtained a Fair Price in its transaction with Novartis
- Bicycle Therapeutics Announces a Strategic Collaboration with Novartis to Discover, Develop and Commercialize Bicycle® Radio-Conjugates
- Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onset
- Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
- Thinking about trading options or stock in AstraZeneca, Jacobs Solutions, J M Smucker, Tesla, or Novartis?
- INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Novartis AG with Losses of $100,000 to Contact the Firm
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
- Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Novartis AG - NVS
- NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
- NOVARTIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Novartis AG on Behalf of Novartis Stockholders and Encourages Investors to Contact the Firm
- Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Novartis AG (NVS) on Behalf of Investors
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Novartis AG (NVS) on Behalf of Investors
- The Law Offices of Frank R. Cruz Announces Investigation of Novartis AG (NVS) on Behalf of Investors
- INTERNATIONAL PROCESS PLANTS ANNOUNCES PURCHASE OF WORLD-CLASS GRIMSBY, UK API PHARMACEUTICAL MANUFACTURING SITE FROM NOVARTIS
- Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
- BeiGene Expands Collaboration with Novartis to Develop and Commercialize BeiGene’s TIGIT Inhibitor and Market Five Novartis Oncology Medicines in China Broad Markets
- Novartis initiates new USD 15 billion share buyback highlighting confidence in growth and pipeline
- Novartis data highlight efficacy of Piqray® in HR+/HER2- metastatic breast cancer with a PIK3CA driver mutation immediately post-CDK4/6i
- Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
- Novartis launches virtual innovation hub to accelerate digital health solutions in sub-Saharan Africa
- LoQus23 Therapeutics exits stealth with £11.5 million seed financing from the Dementia Discovery Fund and Novartis Venture Fund
- Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
- Innodem Neurosciences Signs a Strategic Partnership with Novartis Pharmaceuticals Canada Inc.
- Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
- Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)
- Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
- US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case
